Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, there remains a need for more prevention and treatment options for individuals remaining at risk of ...coronavirus disease 2019 (COVID-19). Monoclonal antibodies (mAbs) against the viral spike protein have potential to both prevent and treat COVID-19 and reduce the risk of severe disease and death. Here, we describe AZD7442, a combination of two mAbs, AZD8895 (tixagevimab) and AZD1061 (cilgavimab), that simultaneously bind to distinct, nonoverlapping epitopes on the spike protein receptor binding domain to neutralize SARS-CoV-2. Initially isolated from individuals with prior SARS-CoV-2 infection, the two mAbs were designed to extend their half-lives and reduce effector functions. The AZD7442 mAbs individually prevent the spike protein from binding to angiotensin-converting enzyme 2 receptor, blocking virus cell entry, and neutralize all tested SARS-CoV-2 variants of concern. In a nonhuman primate model of SARS-CoV-2 infection, prophylactic AZD7442 administration prevented infection, whereas therapeutic administration accelerated virus clearance from the lung. In an ongoing phase 1 study in healthy participants (NCT04507256), a 300-mg intramuscular injection of AZD7442 provided SARS-CoV-2 serum geometric mean neutralizing titers greater than 10-fold above those of convalescent serum for at least 3 months, which remained threefold above those of convalescent serum at 9 months after AZD7442 administration. About 1 to 2% of serum AZD7442 was detected in nasal mucosa, a site of SARS-CoV-2 infection. Extrapolation of the time course of serum AZD7442 concentration suggests AZD7442 may provide up to 12 months of protection and benefit individuals at high-risk of COVID-19.
In the past years a wide discussion has been held among asphalt researchers regarding the existence and interpretation of observed microstructures on bitumen surfaces. To investigate this, the RILEM ...technical committee on nano bituminous materials 231-NBM has conducted a round robin study combining differential scanning calorimetry (DSC) and Atomic Force Microscopy (AFM). From this, methods for performing DSC and AFM tests on bitumen samples and determination of the influence of wax on the observed phases, taking into account thermal history, sample preparation and annealing procedure, are presented and critically discussed. DSC is used to measure various properties and phenomena that indicate physical changes such as glass transition temperature (
T
g
) and phase transition such as melting and crystallization. In the case of existence of wax, either natural or synthetic, it can further indicate the melting point of wax, that could be used to determine wax content. The results from seven laboratories show that
T
g
temperatures obtained from the heating scans are more repeatable and easier to obtain in comparison to the cooling scans. No significant difference was noted for
T
g
’s obtained from the first and second heating scans. AFM is an imaging tool used to characterize the microstructures on a bituminous surface. Using AFM three phases in the materials with wax could be distinguished. The changes in the phases observed with AFM for increases in temperature were correlated with the DSC curve, and it could be established that the so called “Bee” structure disappeared around the melting peak in the DSC curve. Thus, this research has confirmed the relation between the microstructures on a bitumen surface and the wax content.
Triple-negative breast cancer (TNBC) is a collection of biologically diverse cancers characterized by distinct transcriptional patterns, biology, and immune composition. TNBCs subtypes include two ...basal-like (BL1, BL2), a mesenchymal (M) and a luminal androgen receptor (LAR) subtype. Through a comprehensive analysis of mutation, copy number, transcriptomic, epigenetic, proteomic, and phospho-proteomic patterns we describe the genomic landscape of TNBC subtypes. Mesenchymal subtype tumors display high mutation loads, genomic instability, absence of immune cells, low PD-L1 expression, decreased global DNA methylation, and transcriptional repression of antigen presentation genes. We demonstrate that major histocompatibility complex I (MHC-I) is transcriptionally suppressed by H3K27me3 modifications by the polycomb repressor complex 2 (PRC2). Pharmacological inhibition of PRC2 subunits EZH2 or EED restores MHC-I expression and enhances chemotherapy efficacy in murine tumor models, providing a rationale for using PRC2 inhibitors in PD-L1 negative mesenchymal tumors. Subtype-specific differences in immune cell composition and differential genetic/pharmacological vulnerabilities suggest additional treatment strategies for TNBC.
PDF
